European Authorities Approve Advantageous Modifications to Myring™ labelling

  • Removal of requirement for special temperature storage for vaginal contraceptive ring Myring™
  • Competitive advantage in terms of reduced costs and convenience for distributors, pharmacists and patients
  • Similar labelling to be pursued in the United States
Liege, Belgium, 08 November 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that the European Authorities has approved two noteworthy modifications relating to the change in the shelf-life and storage conditions of its vaginal contraceptive ring Myring.

Mithra Signs LSA for Commercialization of Myring™ and Tibelia® in Eastern Europe

  • Mithra grants exclusive license to Aicore Life Sciences for commercialization of Myring™ and Tibelia® in Eastern Europe
  • Production of Myring™ at the Mithra CDMO facility in Belgium
  • Agreement follows licensing deals with major international market leaders for commercialization of Myring™
Liege, Belgium, 24 October 2019 – 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into two exclusive license and supply agreements with Aicore Life Sciences for the registration and commercialization of two major products in contraception and menopause in Eastern Europe: the hormonal contraceptive ring Myring™ and the tibolone-based product Tibelia® for use in Hormone Therapy (HT).

Mithra Signs Agreement for Commercialization of Myring™ in China with Abbott

  • Mithra grants an exclusive license for commercialization of vaginal contraceptive ring in China
  • The introduction of a long acting contraceptive method represents a compelling new alternative for women in China

Liege, Belgium, 14 October 2019, 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has entered into an exclusive license and commercialization agreement with Abbott for the registration and launch of its hormonal contraceptive ring Myring™ in China.

Mithra Signs LSA for Commercialization of Estelle® and Myring™ in Israel

  • Mithra grants exclusive license to Dexcel Pharma for commercialization of its two leading contraceptive products in Israel
  • Dexcel Pharma is Israel’s largest private pharmaceutical company
  • Production at the Mithra CDMO facility in Belgium
Liege, Belgium, 20 August 2019 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into two exclusive license and supply agreements with Dexcel Pharma for the commercialization in Israel of two major products in contraception:  the combined oral pill Estelle® and the hormonal ring Myring™.

Mithra CDMO Strengthens its Management Team and Accelerates Key R&D Programs

  • Strengthening of management team with key appointments of Chief Scientific Officer and Plant Manager, to support the strategy execution of Mithra CDMO
  • Consolidation of R&D and manufacturing teams with 30% increase in highly qualified staff since the beginning of the year
  • Donesta® and PeriNesta® Phase III studies ready to begin, pending approval by authorities
  • Launch of production of Estelle® clinical validation batches for both U.S. and EU filing
  • Positive outcome of the registration procedure for Myring™, adding 15 new Market Authorizations in Europe
Liege, Belgium, 16 July 2019 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces it has strengthened its CDMO Management team with the appointments of Dr Graham Dixon as Chief Scientific Officer and Mr Renaat Baes as Plant Manager.

Mithra Signs LSA for Commercialization of Myring™ in Germany, the biggest market in Europe

  • Mithra grants exclusive license to Hormosan for commercialization of vaginal contraceptive ring in Germany
  • Germany is the largest European market in terms of volumes, with 3 million vaginal rings sold per year
  • Agreement follows licensing deals for Myring™ with market leaders in the U.S., Europe, Russia, Australia, Middle East, Latin and South America

Liege, Belgium, 28 May 2019 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into an exclusive license and supply agreement with Hormosan for the commercialization of its hormonal contraceptive ring Myring™, bioequivalent to Nuvaring®, in Germany. Hormosan is a subsidiary of the innovation-driven pharmaceutical company Lupin Group, offering low-cost generics in Germany that offer added value relevant to therapy.

Tibelia®, First Tibolone-Based Hormone Therapy Approved in Canada

  • The Canadian Health authorities have granted the Marketing Authorization for Tibelia®, the company’s tibolone-based product for use in Hormone Therapy (HT).
  • First tibolone-based hormone treatment to be available in Canada, offering a true new option for women with a proven efficacy, tolerability and safety profile
  • The introduction of Tibelia® in Canada plays a crucial role in the international commercial expansion strategy in key attractive markets like the United States

Liege, Belgium, 15 May 2019 – 7 :30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that Health Canada, the Canadian Health authorities, has approved Tibelia® (tibolone), indicated for the short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women, more than one year after menopause. Developed by Mithra as bioequivalent version of Livial®, Tibelia® is a synthetic steroid that relieves postmenopausal symptoms and prevents osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products.

 

Mithra Signs License and Supply Agreement for Commercialization of Myring™ in Latin and South America

  • Mithra grants exclusive 10-year license to Megalabs for commercialization of vaginal contraceptive ring in Argentina, Paraguay and the Dominican Republic
  • Product to be manufactured at Mithra CDMO facility in Belgium
  • Agreement follows licensing deals for Myring™ with international market leaders in the U.S., Europe, Russia, Australia, Middle East and Chile
Liege, Belgium, 25 April 2019 – 7:30  CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into an exclusive license and supply agreement with the pharmaceutical group Megalabs for the commercialization of its vaginal contraceptive ring Myring™ in Latin America and South America. Based in Uruguay, Megalabs develops a wide range of market-leading pharmaceutical products in twenty Latin American countries.

Mithra announces new agreement with GSP for development of an additional injectable

  • Agreement with Generic Specialty Pharma (GSP), a leading generics player, for development and supply of a fifth hormonal injectable.
  • Expansion of Mithra CDMO’s portfolio of activities, confirming its profile as a unique industrial partner in the development and production of a complete range of specialized medical products and devices.

Liege, Belgium, 18 April 2019 – 7:30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into a new agreement with Generic Speciality Pharma (GSP) for the development and supply of a sterile hormonal injectable product at Mithra CDMO. Headquartered in Dublin, GSP is part of the Alter Pharma group, a Belgian pharmaceutical conglomerate focused on the development and manufacturing of niche generics, complex generics and high added value products.

Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Chile

  • Mithra strengthens its presence in the fast-growing Chilean market with an agreement for commercialization of the hormone treatment Tibelia® with Saval Pharmaceuticals
  • Tibelia® is currently marketed in about ten countries through existing license and supply agreements and just adds an additional market in Spain after winning a public tender

Liege, Belgium, 05 March 2019 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, announces that it has entered into a license and supply agreement with Saval Pharmaceuticals to commercialize Tibelia® in Chile.